GLA
PDLI

Great Lakes Advisors’s PDL BioPharma, Inc. PDLI Stock Holding History

Great Lakes Advisors’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-94,038
Closed -$702K – 575
2014
Q3 		$702K Buy
+94,038
New +$873K 0.02% 356

Other funds holding PDLI

ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Great Lakes Advisors's PDLI Position: Q4 2014 in Review

Great Lakes Advisors sold out of PDL BioPharma, Inc. (PDLI) in Q4 2014, closing a stake of 94,038 shares — an estimated $702K sold.

Great Lakes Advisors first reported a position in PDLI in Q3 2014 and held it in 1 quarter. The position peaked at $702K in Q3 2014. 223 funds tracked by Wall St. Rank hold PDLI as of Q4 2014.

  • Great Lakes Advisors reported no remaining PDL BioPharma, Inc. position as of Q4 2014 after selling out during the quarter.
  • Great Lakes Advisors sold 94,038 PDL BioPharma, Inc. shares in Q4 2014, an estimated $702K.
  • Great Lakes Advisors first reported a position in PDL BioPharma, Inc. in Q3 2014 and held it in 1 quarter.
  • Great Lakes Advisors's PDL BioPharma, Inc. position peaked at $702K in Q3 2014.
  • 223 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2014.

Based on Great Lakes Advisors's 13F filing for Q4 2014, filed 11 Feb 2015.